Development of Keap1-interactive small molecules that regulate Nrf2 transcriptional activity

O'Connell, 2015, The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic, Biochem Soc Trans, 43, 687, 10.1042/BST20150069 Baird, 2013, Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex, Proc Natl Acad Sci USA, 110, 15259, 10.1073/pnas.1305687110 Bertrand, 2015, Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1-Nrf2 protein–protein interaction, J Med Chem, 58, 7186, 10.1021/acs.jmedchem.5b00602 Uruno, 2011, The Keap1-Nrf2 system as an in vivo sensor for electrophiles, Nitric Oxide, 25, 153, 10.1016/j.niox.2011.02.007 Magesh, 2012, Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents, Med Res Rev, 32, 687, 10.1002/med.21257 Baird, 2014, Monitoring Keap1-Nrf2 interactions in single live cells, Biotechnol Adv, 32, 1133, 10.1016/j.biotechadv.2014.03.004 Bomprezzi, 2015, Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview, Ther Adv Neurol Disord, 8, 20, 10.1177/1756285614564152 Wang, 2014, Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties, Drug Des Devel Ther, 8, 2075 Copple, 2014, Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids, Toxicol Sci, 140, 462, 10.1093/toxsci/kfu080 Takaya, 2012, Validation of the multiple sensor mechanism of the Keap1-Nrf2 system, Free Radic Biol Med, 53, 817, 10.1016/j.freeradbiomed.2012.06.023 Cleasby, 2014, Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO, PLoS One, 9, e98896, 10.1371/journal.pone.0098896 Balogun, 2003, Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element, Biochem J, 371, 887, 10.1042/bj20021619 Soetikno, 2013, Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway, Mol Nutr Food Res, 57, 1649, 10.1002/mnfr.201200540 Shen, 2015, A curcumin derivative that inhibits vinyl carbamate-induced lung carcinogenesis via activation of the Nrf2 protective response, Antioxid Redox Signal, 23, 651, 10.1089/ars.2014.6074 Gupta, 2013, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J, 15, 195, 10.1208/s12248-012-9432-8 Wilson, 2013, Keap calm, and carry on covalently, J Med Chem, 56, 7463, 10.1021/jm400224q Satoh, 2006, Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers, Proc Natl Acad Sci USA, 103, 768, 10.1073/pnas.0505723102 Guerrero-Beltran, 2012, Protective effect of sulforaphane against oxidative stress: recent advances, Exp Toxicol Pathol, 64, 503, 10.1016/j.etp.2010.11.005 Hu, 2011, Modification of keap1 cysteine residues by sulforaphane, Chem Res Toxicol, 24, 515, 10.1021/tx100389r Zhang, 2003, Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress, Mol Cell Biol, 23, 8137, 10.1128/MCB.23.22.8137-8151.2003 Kobayashi, 2009, The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds, Mol Cell Biol., 29, 493, 10.1128/MCB.01080-08 Lozanovski, 2014, Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) – study protocol for a randomized controlled trial, Trials, 15, 204, 10.1186/1745-6215-15-204 Mirmiran, 2012, Effects of broccoli sprout with high sulforaphane concentration on inflammatory markers in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial, J Funct Foods, 4, 837, 10.1016/j.jff.2012.05.012 Morroni, 2013, Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease, Neurotoxicology, 36, 63, 10.1016/j.neuro.2013.03.004 Singh, 2014, Sulforaphane treatment of autism spectrum disorder (ASD), Proc Natl Acad Sci USA, 111, 15550, 10.1073/pnas.1416940111 Tufekci, 2011, The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease, Parkinsons Dis, 2011, 314082 Abed, 2015, Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents, Acta Pharm Sin B, 5, 285, 10.1016/j.apsb.2015.05.008 Cheung, 2010, Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention, AAPS J, 12, 87, 10.1208/s12248-009-9162-8 Durham, 2014, The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway, Eur Respir J, 44 Greaney, 2016, Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism, J Leukoc Biol, 99, 189, 10.1189/jlb.3A0415-155RR Jo, 2014, Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52, Nat Commun, 5, 3496, 10.1038/ncomms4496 Yanaka, 2014, Adaptive cytoprotection and cancer chemoprotection by sulforaphane against various stresses: role of nrf2-keap1 dependent and independent pathways (1052.1), FASEB J, 28 Wells, 2015, Peptide and small molecule inhibitors of the Keap1-Nrf2 protein–protein interaction, Biochem Soc Trans, 43, 674, 10.1042/BST20150051 Fukutomi, 2014, Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1, Mol Cell Biol, 34, 832, 10.1128/MCB.01191-13 Lo, 2006, Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling, EMBO J, 25, 3605, 10.1038/sj.emboj.7601243 Tong, 2007, Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response, Mol Cell Biol, 27, 7511, 10.1128/MCB.00753-07 Chen, 2011, Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance, Chem Biol Drug Des, 78, 1014, 10.1111/j.1747-0285.2011.01240.x Hancock, 2012, Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction, Free Radic Biol Med, 52, 444, 10.1016/j.freeradbiomed.2011.10.486 Lu, 2015, Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors, RSC Adv, 5, 85983, 10.1039/C5RA16262A Hancock, 2013, Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity, Org Biomol Chem, 11, 3553, 10.1039/c3ob40249e Steel, 2012, Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interaction, ACS Med Chem Lett, 3, 407, 10.1021/ml300041g Hu, 2013, Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein–protein interaction, Bioorg Med Chem Lett, 23, 3039, 10.1016/j.bmcl.2013.03.013 Wen, 2015, Activation of NRF2 signaling in HEK293 cells by a first-in-class direct KEAP1-NRF2 inhibitor, J Biochem Mol Toxicol, 29, 261, 10.1002/jbt.21693 Jnoff, 2014, Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex, ChemMedChem, 9, 699, 10.1002/cmdc.201300525 Marcotte, 2013, Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism, Bioorg Med Chem, 21, 4011, 10.1016/j.bmc.2013.04.019 Jiang, 2014, Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis, J Med Chem, 57, 2736, 10.1021/jm5000529 Jain, 2015, Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators, Eur J Med Chem, 103, 252, 10.1016/j.ejmech.2015.08.049 Jiang, 2015, Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein–protein interaction inhibitor, J Med Chem, 58, 6410, 10.1021/acs.jmedchem.5b00185 Winkel, 2015, Characterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling, J Biol Chem, 290, 28446, 10.1074/jbc.M115.678136 Lu, 2016, An inhibitor of the Keap1-Nrf2 protein–protein interaction protects NCM460 colonic cells and alleviates experimental colitis, Sci Rep, 6, 26585, 10.1038/srep26585 Davies, 2016, Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery, J Med Chem, 59, 3991, 10.1021/acs.jmedchem.6b00228 Shimozono, 2013, Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model, Mol Pharmacol, 84, 62, 10.1124/mol.112.084269 Satoh, 2015, Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation, FEBS Open Bio, 5, 557, 10.1016/j.fob.2015.06.011 East, 2014, PMI: A ΔΨm independent pharmacological regulator of mitophagy, Chem Biol, 21, 1585, 10.1016/j.chembiol.2014.09.019 Redmann, 2014, Mitophagy mechanisms and role in human diseases, Int J Biochem Cell Biol, 53, 127, 10.1016/j.biocel.2014.05.010 Narendra, 2014, Parkin-induced mitophagy in the pathogenesis of Parkinson disease, Autophagy, 5, 706, 10.4161/auto.5.5.8505 Zhang, 2013, Bardoxolone brings Nrf2-based therapies to light, Antioxid Redox Signal, 19, 517, 10.1089/ars.2012.5118